Al-Ola Abdallah, Director of Plasma Cell Disorders Care at The University of Kansas Health System and Chair of USMIRC, shared Vincent Rajkumar, Professor of Medicine at the Mayo Clinic in Rochester and Editor‑in‑Chief at Blood Cancer Journal, post on X, adding:
“The final AQUILA analysis at ASH2026 showed that early daratumumab improved both progression-free survival and overall survival in high-risk smoldering myeloma. At 7 years, overall survival was 87.8% with daratumumab versus 78.7% with active monitoring (HR 0.52).
Here in Kansas this has been the SOC!”
Quoting Vincent Rajkumar’s post:
“Just out ASH abstracts online: I will present overall survival results of AQUILA trial in high risk smoldering myeloma at ASH26.
Overall survival was significantly improved with Dara; significant 48% reduction in risk of death (HR 0.52; 95% CI, 0.32–0.87; P=0.0108). The 7-year OS rate was 87.8% with Dara versus 78.7% with observation. Learn more at the live meeting.”
Title: 112 Daratumumab monotherapy improves overall survival in patients with high-risk smoldering multiple myeloma: Final analyses of survival outcomes from the phase 3 AQUILA study
Authors: S. Vincent Rajkumar, Peter Voorhees, Fredrik Schjesvold, Yael C. Cohen, Vania Hungria, Irwindeep Sandhu, Jindriska Lindsay, Ross Baker, Kenshi Suzuki, Hiroshi Kosugi, Mark-David Levin, Meral Beksac, Keith Stockerl-Goldstein, Albert Oriol Sr, Gabor Mikala, Gonzalo Garate, Koen Theunissen, Ivan Špicka, Anne Mylin, Sara Bringhen, Katarina Uttervall, Bartosz Pula, Eva Medvedova, Andrew J. Cowan, Philippe Moreau Sr, Maria-Victoria Mateos Jr, Hartmut Goldschmidt, Tahamtan Ahmadi, Linlin Sha, Els Rousseau, Liang Li, Robyn Dennis, Robin Carson, Meletios-Athanasios (Thanos) C. Dimopoulos
You can also read:
Elranatamab in High-Risk Smoldering Myeloma: First Results From the Phase 2 ERASMM Study
